Skip to main content
Premium Trial:

Request an Annual Quote

Jim Wright, Aiping Young

Antisense drug developer Lorus Therapeutics said this week that President and CEO Jim Wright has resigned.
According to the company, Wright will continue to be associated with Lorus as a director and special advisor.
Lorus also announced that Aiping Young has been appointed the firm’s new president and CEO.
Young has held a number of positions at Lorus, including vice president of research and development, CTO, and COO. Most recently, he was vice president of research for Lorus subsidiary GeneSense Technologies.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.